Organon (NYSE:OGN) Azioni

Organon

Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Gli analisti più esperti indicano 3 società con rendimenti consistenti. Un&#39;analisi approfondita per un portafoglio più stabile e redditizio.

Dividendi da urlo nel settore sanitario! 3 titoli segnalati dagli esperti

UBS analyst Joseph Spak upgrades American Axle &amp; Mfg Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXL#NYSE">AXL</a>) from Neutral to Buy and raises the price target from $4.5 to $7.

Upgrades

UBS Upgrades American Axle & Mfg Hldgs to Buy, Raises Price Target to $7

Macy's, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) (the "Company") announced today that its wholly-owned subsidiary, Macy's Retail Holdings, LLC (the "Issuer"), intends to offer, subject to market and other customary conditions, $500 million in aggregate principal amount of senior notes due 2033 (the "Notes") in a private offering. The Notes will be senior unsecured obligations of the Issuer and will be unconditionally guaranteed on a senior unsecured basis by the Company.
The Issuer intends to use the proceeds from the offering of the Notes, together with cash on hand, to (i) fund its separately announced concurrent tender offer (the "Tender Offer"), (ii) redeem approximately $587 million of certain of its existing outstanding senior notes and debentures (such redemption, the "Redemption") and (iii) pay fees, premium and expenses in connection therewith and this offering. The Redemption and the Tender Offer are conditioned on, among other things, the consummation of the offering of the Notes. The offering of the Notes, however, is not conditioned on the consummation of the Redemption or the Tender Offer (including the tender of any specified amount of the Company's outstanding senior notes as part of the Tender Offer). This press release does not constitute an offer to purchase, a solicitation of an offer to sell or a notice with respect to any tender offer or redemption of any existing notes.

Offerings

Macy's Plans $500M Bond Sale to Restructure Debt and Buy Back Older Notes

Morgan Stanley analyst Chris Quintero initiates coverage on Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) with a Underweight rating and announces Price Target of $190.

Initiation

MANH

Morgan Stanley Initiates Coverage On Manhattan Associates with Underweight Rating, Announces Price Target of $190

EPIX

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

VBTX

Aurora Mobile Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JG#NASDAQ">JG</a>) surged Monday as investors bet on its mobile analytics and marketing tools <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46386735/aurora-mobile-highlights-growth-potential-amid-bitcoin-surge" rel="noreferrer noopener">benefiting from renewed momentum</a> in the cryptocurrency market.
Bitcoin&#8217;s (CRYPTO: BTC/USD) recent <a target="_blank" href="https://www.benzinga.com/crypto/25/07/46385051/bitcoin-zooms-past-121000-to-finish-historic-week-whats-fueling-the-rally" rel="noreferrer noopener">surge</a> to a record $119,000 on July 13, 2025, has accelerated interest in firms connected to the crypto economy. As blockchain adoption grows, so does the need for intelligent customer engagement solutions across the digital finance landscape.
Aurora Mobile helps exchanges, wallet apps, and fintech platforms reach their audiences more effectively through AI-powered messaging and data insights. Its marketing tools allow companies to understand user behavior better, enhance retention, and improve communication strategies across mobile platforms.
Also Read: <a target="_blank" href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46388685/bitcoin-shatters-all-time-high-to-hit-123000-as-ethereum-cracks-3000-and-xrp-taps-3" rel="noreferrer noopener">Bitcoin Shatters All-Time High To Hit $123,000 As Ethereum Cracks $3,000 And XRP Taps $3</a>
Founded in 2011, Aurora Mobile has grown from a messaging provider into a leading marketing tech firm. It leverages cloud services and data analytics to support digital transformation in China&#8217;s mobile market.
With the continued rise of cryptocurrencies and increasing user activity across decentralized platforms, Aurora Mobile aims to serve as a key bridge between traditional marketing strategies and the unique demands of blockchain-related businesses. The company&#8217;s data-driven approach seeks to address the shifting landscape of how digital services engage and retain users.
Aurora Mobile recently <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46361580/aurora-mobile-evaluates-solana-sol-for-its-cryptocurrency-treasury-strategy" rel="noreferrer noopener">announced</a> that it is evaluating the integration of Solana into its cryptocurrency treasury strategy, which was approved by the board in June. CEO Weidong Luo cited Solana&#8217;s speed, low transaction costs, and rising institutional adoption as key factors, framing the move as a long-term strategic initiative rather than a speculative bet.
Related ETFs: Amplify Transformational Data Sharing ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLOK#NYSE">BLOK</a>), Global X Blockchain ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKCH#NASDAQ">BKCH</a>)
Price Action: JG shares were trading higher by 7.44% to $12.57 premarket at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46387048/bitcoin-is-humanitys-best-bet-against-currency-debasement-says-anthony-pompliano-we-owe-so-" target="_blank" rel="noreferrer noopener">Bitcoin Is Humanity&#8217;s &#8216;Best Bet&#8217; Against Currency Debasement, Says Anthony Pompliano: &#8216;We Owe So Much To Satoshi Nakamoto&#8217;</a></li>
</ul>
Image via Shutterstock

Movers

Tech

BKCH

BLOK

Why Is Aurora Mobile Stock Soaring On Monday?

Scotiabank analyst Greg Harrison initiates coverage on Gossamer Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) with a Sector Outperform rating and announces Price Target of $11.

GOSS

Scotiabank Initiates Coverage On Gossamer Bio with Sector Outperform Rating, Announces Price Target of $11

Morgan Stanley analyst Jeffrey Hung maintains Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Overweight and lowers the price target from $65 to $55.

RARE

Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $55

Morgan Stanley analyst Hamza Fodderwala downgrades CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) from Overweight to Equal-Weight and raises the price target from $490 to $495.

Downgrades

CRWD

Morgan Stanley Downgrades CrowdStrike Holdings to Equal-Weight, Raises Price Target to $495

Viomi Technology Co., Ltd ("Viomi" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIOT#NASDAQ">VIOT</a>), a leading technology company for home water solutions in China, today announced that its board of directors has approved the declaration and distribution of a special dividend (the "Special Dividend") of US$0.0293 per ordinary share (US$0.0880 per American depositary share, or ADS). The aggregate amount of the Special Dividend will be approximately US$6 million. The Special Dividend is&nbsp;expected to be paid on or around August 18, 2025 to the holders of the Company's ordinary shares, and on or around August 21, 2025 to the holders of the Company's ADSs, of record, as of the close of business on July 31, 2025. The Special Dividend to be paid to the holders of ADSs will be subject to the terms of the deposit agreement.

VIOT

Viomi Technology Board Approves Declaration And Distribution Of Special Dividend Of $0.0293 Per Ordinary Share

Citigroup analyst Patrick Donnelly initiates coverage on Caris Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAI#NASDAQ">CAI</a>) with a Buy rating and announces Price Target of $34.

Citigroup Initiates Coverage On Caris Life Sciences with Buy Rating, Announces Price Target of $34

Morgan Stanley initiates coverage on Slide Insurance Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDE#NASDAQ">SLDE</a>) with a Equal-Weight rating and announces Price Target of $19.

SLDE

Morgan Stanley Initiates Coverage On Slide Insurance Holdings with Equal-Weight Rating, Announces Price Target of $19

Piper Sandler analyst James Fish maintains Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) with a Overweight and raises the price target from $121 to $140.

TWLO

Piper Sandler Maintains Overweight on Twilio, Raises Price Target to $140

Firefly Neuroscience, Inc. ("Firefly" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to highlight its ongoing collaboration with Prof. Dr. med. Christian Schaaf, Director of the Institute of Human Genetics at Heidelberg University Hospital and Chairman of Human Genetics at the Medical Faculty of Heidelberg University, on a groundbreaking study investigating the neurophysiological impact of 15q13.3 copy number variants ("CNVs"). This engagement builds on prior work between Firefly and Prof. Schaaf, including a joint publication on CHRNA7-related phenotypes.1
The current study leverages Firefly's FDA-cleared technology to analyze Electroencephalograms ("EEG") data from 30 subjects — 15 with deletions and 15 with duplications of the 15q13.3 chromosomal region. Study subjects undergo resting state and two cognitive paradigms running automatically through Firefly's BNA platform.
The study is scheduled to run through 2026, with Firefly commercially engaged to provide EEG systems, training, and full analytic support, including the comparison to its proprietary, FDA-cleared normative Resting and Event-Related Potential Cognitive tasks database.
The study aims to:
<ol>
<li>Identify electrophysiological biomarkers associated with 15q13.3 CNVs;</li>
<li>Characterize neurocognitive profiles linked to deletions vs. duplications; and</li>
<li>Support future diagnostic and therapeutic strategies for neurodevelopmental disorders. &nbsp;</li>
</ol>

AIFF

Firefly Neuroscience Teams With German Hospital to Study Rare Brain Disorders Using AI and EEG

The European Union has a €21 billion ($24.52 billion) package of tariffs on U.S. goods ready for implementation should ongoing trade negotiations falter, Italy&#8217;s Foreign Minister Antonio Tajani stated in a newspaper interview on Monday, as reported by Reuters.
What Happened: This readiness comes in response to U.S. President Donald Trump&#8216;s recent threat to impose a <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46384885/peter-schiff-gives-trumps-30-tariff-threat-on-mexico-eu-a-reality-check-america-relies-on-deficits-to-make-up-for-excess-debt-and-consumption">30% tariff on imports</a> from both Mexico and the EU beginning Aug. 1, following weeks of inconclusive discussions with major trading partners. 
According to Reuters, Tajani informed the daily Il Messaggero that a second set of tariffs could follow the initial €21 billion package if a comprehensive deal with the U.S. proves unattainable.
Despite the escalating tensions, Tajani expressed confidence in the potential for progress in negotiations, emphasizing that &#8220;Tariffs hurt every one, starting with the United States.&#8221;
He further warned that declining stock markets due to tariffs would jeopardize &#8220;the pensions and the savings of the Americans,&#8221; advocating instead for a goal of &#8220;zero tariffs&#8221; and an open market spanning Canada, the United States, Mexico, and Europe.
See Also: <a href="https://www.benzinga.com/news/politics/25/07/46386524/trump-wants-blanket-tariffs-of-up-to-20-after-surprise-treasury-surplus-in-june-ed-yardeni-says-don">Trump Wants Blanket Tariffs Of Up To 20% After Surprise Treasury Surplus In June: Ed Yardeni Says &#8216;Don&#8217;t Push Your Luck&#8217;</a>
Why It Matters: In related developments, the EU announced on Sunday its decision to extend the suspension of countermeasures to U.S. tariffs until early August, aiming to continue pushing for a negotiated settlement.
Reuters also highlighted comments from German Chancellor Friedrich Merz, who on Sunday pledged to collaborate closely with French President Emmanuel Macron and European Commission President Ursula von der Leyen to de-escalate the burgeoning trade dispute.
Echoing the sentiment for a resolution, European Trade Commissioner Maros Sefcovic stated on Monday that Washington and Brussels were nearing a mutually beneficial outcome, cautioning that a 30% tariff would effectively &#8220;practically eliminate trade.&#8221;
In a Sunday post on X, Peter Schiff cautioned against Trump&#8217;s rationale for 30% tariffs, which states that reducing trade deficits with these regions signifies <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46384885/peter-schiff-gives-trumps-30-tariff-threat-on-mexico-eu-a-reality-check-america-relies-on-deficits-to-make-up-for-excess-debt-and-consumption">unfair economic arrangements</a>. 
Schiff, however, disputes this premise, contending that these deficits stem from more profound structural issues within the American economy, rather than being a consequence of disadvantageous or inequitable trade agreements. &#8220;He blames unfair trade for our deficits,&#8221; Schiff stated, further clarifying that these deficits are, in fact, &#8220;the result of excessive debt and consumption, alongside inadequate savings and investment.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Trump just threatened 30% tariffs on all Mexican and European imports starting August 1st. He blames unfair trade for our deficits. But America relies on those deficits to compensate for the consequences of excessive debt and consumption, and inadequate savings and investment.
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1944041820897317042?ref_src=twsrc%5Etfw">July 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket on Monday. The SPY was down 0.32% at $621.60, while the QQQ declined 0.34% to $552.31, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/hedge-funds/25/07/46386374/stanley-druckenmillers-duquesne-dumps-palantir-bets-big-on-this-dividend-play-which-has-surge" target="_blank" rel="noreferrer noopener">Stanley Druckenmiller's Duquesne Dumps Palantir, Bets Big On This Dividend Play Which Has Surged Nearly 50% In 2025</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. 
Image via Shutterstock

EU Prepares $24.5B In Tariffs As Trump Threatens 30% Import Tax On Mexico, Europe

Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith initiates coverage on Slide Insurance Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDE#NASDAQ">SLDE</a>) with a Market Perform rating and announces Price Target of $20.

Keefe, Bruyette & Woods Initiates Coverage On Slide Insurance Holdings with Market Perform Rating, Announces Price Target of $20

Barclays analyst Christine Cho upgrades SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) from Underweight to Equal-Weight and raises the price target from $12 to $29.

SEDG

Barclays Upgrades SolarEdge Technologies to Equal-Weight, Raises Price Target to $29

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Piper Sandler analyst Peter Keith downgraded the rating for Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) from Overweight to Neutral and lowered the price target from $82 to $75. Best Buy shares closed at $71.79 on Friday. <a href="https://www.benzinga.com/quote/BBY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Jeff Johnson downgraded Henry Schein, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) from Outperform to Neutral and lowered the price target from $82 to $72. Henry Schein shares closed at $73.42 on Thursday. <a href="https://www.benzinga.com/quote/HSIC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group analyst Robert Ottenstein downgraded the rating for The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) from Outperform to In-Line and slashed the price target from $190 to $170. Procter &amp; Gamble shares closed at $157.05 on Friday. <a href="https://www.benzinga.com/quote/PG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Andrew Steinerman downgraded Vestis Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTS#NYSE">VSTS</a>) from Neutral to Underweight but raised the price target from $5 to $6. Vestis shares closed at $6.14 on Friday. <a href="https://www.benzinga.com/quote/VSTS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Raghuram Selvaraju downgraded Verona Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) from Buy to Neutral but raised the price target from $90 to $107. Verona Pharma shares closed at $104.83 on Friday. <a href="https://www.benzinga.com/quote/VRNA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/PG/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="563" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14073747/image-153-1024x563.png" alt="" class="wp-image-983807" style="width:586px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14073747/image-153-1024x563.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14073747/image-153-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14073747/image-153-768x422.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14073747/image-153.png 1140w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46388321/top-3-health-care-stocks-that-could-blast-off-in-july">: </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46388321/top-3-health-care-stocks-that-could-blast-off-in-july">Top 3 Health Care Stocks That Could Blast Off In July</a></li>
</ul>
Photo via Shutterstock

HSIC

VRNA

VSTS

This Procter & Gamble Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

TD Cowen analyst Robert Moskow upgrades WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) from Sell to Hold and raises the price target from $14 to $23.

TD Cowen Upgrades WK Kellogg to Hold, Raises Price Target to $23

Keefe, Bruyette &amp; Woods analyst Aidan Hall maintains PJT Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJT#NYSE">PJT</a>) with a Market Perform and raises the price target from $161 to $199.

Keefe, Bruyette & Woods Maintains Market Perform on PJT Partners, Raises Price Target to $199

Press Releases

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Organon & Co.(OGN) Shareholders

Legal

Deadline Alert: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

OGN Deadline: OGN Investors with Losses in Excess of $100K Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit

Organon & Co. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before July 22, 2025 to Discuss Your Rights – OGN

ORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Organon & Co. - OGN

OGN FRAUD ALERT: Organon & Co. 27% Stock Drop Triggers Securities Fraud Class Action – Investors Notified to Contact BFA Law by July 22 (NYSE:OGN)

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co. of Class Action Lawsuit and Upcoming Deadlines - OGN

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Organon, UroGen and Fortrea and Encourages Investors to Contact the Firm

OGN IMPORTANT DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Organon & Co. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 22 Deadline in Securities Class Action – OGN

Comments

Organon

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO